Biomea Fusion presented positive data on icovamenib for type 2 diabetes, showing improved glycemic control and weight loss in clinical trials. Biomea Fusion announced promising new data for icovamenib ...
The European Medicines Agency (EMA) has approved an extension to the licensed indications for Mounjaro (tirzepatide, Eli Lilly Nederland B.V.) to enable its use for the treatment of type 2 diabetes ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results